Percentage of Organizations with Matured Cloud Adoption in Each Country
Cloud is moving into a second wave of adoption. Organizations are leveraging cloud to fuel innovation, growth, and disruption.
Radware (RDWR) is a global leader of application delivery. It provides a security solution for virtual, cloud, and software-defined data centers.
Splunk generated returns of -1.38% in the TTM and -15.50% in the trailing one-month period. Its share price fell by 3.87% in the trailing five-day period.
Splunk (SPLK) shares fell by 5.10% to $60.98 despite strong 2Q15 results. It reported total revenue of $148.3 million compared to $101.5 million last year.
Application software is the worst performing sector. It generated a return of -4.75%. Within the sector, Gemalto (GTO) generated returns of -13.65%.
Patterson Companies (PDCO) makes up 0.14% of the Health Care Select Sector SPDR ETF (XLV). PDCO has a market cap of ~$4.7 billion.
Patterson Companies was the worst performer within the Health Care Select Sector SPDR ETF (XLV) for the period between August 25 and August 31, with a return of -4.10%.
Vertex Pharmaceuticals (VRTX) has outperformed other stocks within the Health Care Select Sector SPDR ETF (XLV) with a return of 6.92% for the period between August 25 and August 31.
Vertex Pharmaceuticals (VRTX) makes up 1.19% of the Health Care Select Sector SPDR ETF (XLV). It has a market cap of ~$31 billion.
PerkinElmer (PKI) with a return of 5.94% was the best performer of XLV’s bottom ten stocks.
Though most of the biotech stocks rebounded from the recent lows, the long-term trend for biotech seems to be heading downward.
The Health Care Select Sector SPDR ETF (XLV) rose by 2.68% between August 25 and August 31, as 49 of its 55 stocks had positive returns.
The iShares NASDAQ Biotechnology ETF (IBB) has 14 American Depository Receipts (ADR) in its portfolio. These ADRs have a weight of 9.36% and gave an average return of 0.85% for August 10–17, 2015.
From August 10–17, 2015, the XBI top ten small-cap stocks outperformed the IBB’s top ten small-cap stocks. XBI small caps returned 1.04% while IBB small caps rose by 0.07% during the same period.
In the mid-cap space, the iShares NASDAQ Biotechnology ETF’s (IBB) top ten stocks outperformed the SPDR S&P Biotech ETF’s (XBI) top ten stocks.
On August 4, Incyte announced better-than-expected 2Q15 results. Its 2Q15 revenues were $163 million, compared to $100 million in 2Q14.
The iShares NASDAQ Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) provide investors with an opportunity to hold a basket of stocks from different subindustries from the biotech sector.
Incyte (INCY) is one of the key players in oncology. It concentrates in curing Myelofibrosis and polycythemia—rare kinds of blood cancer.
Opko Health (OPK) makes up 1.25% of the SPDR S&P Biotech ETF (XBI). It is a mid-cap stock and has a market cap of ~$6 billion.
The SPDR S&P Biotechnology ETF’s (XBI) pharmaceutical subgroup contains 31 stocks, which make up 32.21% of the ETF’s portfolio.